Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting
In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…Abstract Number: 2453 • 2017 ACR/ARHP Annual Meeting
Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months
Background/Purpose: Methotrexate is frequently administered in combination with biologics for the therapy of Rheumatoid Arthritis (RA) as it leads to superior outcomes compared to biologic…Abstract Number: 2454 • 2017 ACR/ARHP Annual Meeting
Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: Adalimumab (ADA) was approved in the US in 2002 for rheumatoid arthritis (RA), and subsequently approved for the management of other inflammatory diseases such…Abstract Number: 2455 • 2017 ACR/ARHP Annual Meeting
Efficacy of Etanercept in Elderly Patients with Rheumatoid Arthritis
Background/Purpose: Ageing is associated with declining immune cell function and age-related comorbidities.1,2 In the US, the prevalence of rheumatoid arthritis (RA) is ~2% in individuals…Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting
Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)
Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…Abstract Number: 2457 • 2017 ACR/ARHP Annual Meeting
Sarilumab for the Treatment of Active, Moderate-to-Severe Rheumatoid Arthritis (RA): An Analysis of Cost per Effectively Treated Patient
Background/Purpose: The MONARCH study (NCT02332590) evaluated monotherapy with sarilumab 200 mg subcutaneous (SC) + placebo every 2 weeks (Q2W) versus adalimumab 40 mg SC +…Abstract Number: 2458 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy
Background/Purpose: In early rheumatoid arthritis (RA), starting therapy as soon as possible is important to reduce disease activity and preserve the joints. With application of…Abstract Number: 2459 • 2017 ACR/ARHP Annual Meeting
Incidence of Disease Worsening in Inflammatory Arthritis Patients on Long-Term Infliximab (Remicade®) Therapy
Background/Purpose: A recent randomized controlled study in a single country reported rates of disease worsening over a one-year follow-up period for innovator infliximab (IFX) and…Abstract Number: 2460 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Background/Purpose: Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce…Abstract Number: 2461 • 2017 ACR/ARHP Annual Meeting
Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study
Background/Purpose: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in RA patients.1 However, there are limited…Abstract Number: 2462 • 2017 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Rheumatoid Arthritis: A Retrospective Study
Background/Purpose: Current guidelines on RA treatment recommend tapering of biologic DMARDs for patients in persistent remission. Methods: In this retrospective study we used the hospital…Abstract Number: 2463 • 2017 ACR/ARHP Annual Meeting
Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in several randomized clinical trials with biologic-naïve patients (pts.). However, more data regarding the effectiveness and patient-reported…Abstract Number: 2464 • 2017 ACR/ARHP Annual Meeting
Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life
Background/Purpose: It has been proven, in a pivotal RCT, that SC TCZ was non-inferior to IV TCZ [1]. However, the effectiveness of the SC TCZ…Abstract Number: 2465 • 2017 ACR/ARHP Annual Meeting
Association between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis: A Multiple Imputation Approach
Background/Purpose: Methotrexate (MTX) is recommended and widely prescribed as the first-line, evidence-based therapy for rheumatoid arthritis (RA) patients. Previous studies have demonstrated a significant effect…Abstract Number: 2466 • 2017 ACR/ARHP Annual Meeting
Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB2 or Reference Infliximab
Background/Purpose: Based on the totality of evidence, SB2 has shown to be similar with reference infliximab (INF) and has been approved as a biosimilar by…
ACR Meeting Abstracts